Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: Contribution of spinal dopamine receptors

Fundamental and Clinical Pharmacology

Volumn 12, Issue 6, 1998, Pages 599-606

  Lahlou, S ^a   Pinto Duarte, G ^a  

^a DEPARTAMENTO DE MICOLOGIA   (Brazil)

Author keywords

Blood pressure; Bromocriptine; DOCA salt hypertension; Intrathecal domperidone; Spinal dopamine D2 receptors

Indexed keywords

BROMOCRIPTINE MESILATE; DEOXYCORTICOSTERONE ACETATE; DOMPERIDONE; DOPAMINE RECEPTOR; METOCLOPRAMIDE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; AORTA PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; HYPOTENSION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032287132     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00992.x     Document Type: Article

References (53)

1. Miyai K, Onishi T, Hosokawa K, Kumahara Y. Inhibition of hyrotropin and prolactin secretions in primary hypothyroidism by 2-Br-alpha-ergocryptine. J Clin Endocrinol Metab 1974 ; 39: 391-4
2. Lieberman A, Zolfaghari M, Boal D, Hassouri H, Vogel B, Battista A et al. The antiparkinsonian efficacy of bromocriptine. Neurology 1976 ; 26: 405-9
3. Stumpe KO, Kolloch R, Higuchi M, Krück F, Vetter H. Hyperprolactinaemia and antihypertensive effect of bromocriptine in essential hypertension. Lancet 1977 ; 2 : 211-4
4. Kulloch R, Kobayashi K, DeQuattro V. Dopaminergic control ot sympathetic tone and blood pressure: evidence in primary hypertension. Hypertension 1980 ; 2: 390-4
5. Montastruc JL, Chamontin B, Rascol A. Parkinson's disease and hypertension: chronic bromocriptine treatment. Neurology 1985 ; 35: 1644-7
6. Luchsinger A, Grilli M, Forte P, Morales E, Velasco M. Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive patients. Int J Clin Pharmacol Ther 1995 ; 33: 509-12
7. Hamilton TC. Involvement of the adrenal glands in the hypotensive response to bromocriptine in conscious spontaneously hypertensive rats. Br J Pharmacol 1981 ; 72: 419-25
8. Tadepalli AS, Novak PJ. Cardiovascular effects of bromocriptine and lergotrile in renal and spontaneously hypertensive rats. Arch Int Pharmacodyn Ther 1983 ; 266: 93-105
9. Nagahama S, Chen YF, Oparil S. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. J Pharmacol Exp Ther 1984 ; 228: 370-5
10. Racz K, Kuchel O, Bun NT. Bromocriptine decreases blood pressure in spontaneously hypertensive rats without affecting the adrenomedullary synthesis of catecholamines. J Cardiovasc Pharmacol 1986 ; 8: 676-80
11. Van den Buuse M, Lambrechts AC. Bromocriptine-induced decrease in blood pressure in conscious spontaneously hypertensive rats: evidence for a peripheral site of action. J Pharm Pharmacol 1989 ; 41: 644-6
12. Nagahama S, Chen YF, Oparil S. Enhanced depressor effect of bromocriptine in the DOCA/NaCl hypertensive rat. Am J Physiol 1985 ; 249: H64-70
13. Roquebert J, Alaoui K, Morán Benito A. Cardiovascular effects of bromocriptine in rats: role of peripheral adrenergic and dopaminergic receptors. J Auton Pharmacol 1990 ; 10: 85-96
14. Lahlou S, Demenge P. Contribution of spinal dopamine receptors to the hypotensive action of bromocriptine in rats. J Cardiovasc Pharmacol 1991 ; 18: 317-25
15. Lahlou S, Demenge P. Increase in the hypotensive effect of bromocriptine induced by spinal transection in rats: contribution of spinal dopamine receptors. J Cardiovasc Pharmacol 1992 ; 19: 723-31
16. Lahlou S, Pinto Duarte G, Demenge P. Central dopaminergic origin of bromocriptine induced tachycardia in normotensive rats. Cardiovasc Res 1993 ; 27: 2022-7
17. Lokhandwala MF. Analysis of the effects of bromocriptine on blood pressure and sympathetic nerve function. Eur J Pharmacol 1979 ; 56: 253-6
18. Montastruc JL, Montastruc P. The role of the adrenal medulla in the antihypertensive action of bromocriptine in neurogenic hypertensive dogs. J Pharmacol (Paris) 1983 ; 14: 183-7
19. Laduron PM, Leysen JE. Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity. Biochem Pharmacol 1979 ; 28: 2161-5
20. Sved AF, Fernstrom JD. Evidence for a peripheral dopaminergic mechanism in the antihypertensive action of lergotrile. Life Sci 1980; 27: 349-54
21. Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 1983 ; 89: 137-41
22. Champion MC. Domperidone. Gen Pharmac 1988 ; 19: 499-505
23. 11 cell group to the spinal cord. Acta Physiol Scand 1979 ; 107 : 393-5
24. Skagerberg G, Björklund A, Lindvall O, Schmidt RH. Origin and termination of the diencephalo-spinal dopamine system in the rat. Brain Res Bull 1982 ; 9: 237-44
25. Mouchet P, Petitjean P, Guérin B, Munier M, Pellissier G, Feuerstein C et al. Le système dopaminergique spinal. J Pharmacol (Paris) 1986 ; 17: 523-40
26. Feuerstein C, Mouchet P, Manier M, Moussaoui S, Mons N, Geffard M et al. Dopaminergic relationships in the rat spinal cord. In: Sandler M, Dahlstrom A, Belmaker RH, eds. Progress in Catecholamine Research, Part B: Central Aspects. New York: Alan R. Liss; 1988. p 529-36
27. Demenge P, Mouchet P, Guérin B, Feuerstein C. Identification and distribution of neuroleptic binding sites in the rat spinal cord. J Neurochem 1981 ; 37: 53-9
28. 2 dopamine receptors. Neuroscience 1986 ; 19: 125-37
29. 2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 1996 ; 8: 621-8
30. Petitjean P, Mouchet P, Pellissier G, Manier M, Feuerstein C, Demenge P. Cardiovascular effects in the rat of intrathecal injections of apomorphine at the thoracic spinal cord level. Eur J Pharmacol 1984 ; 105: 355-9
31. Lahlou S, Petitjean P, Pellissier G, Mouchet P, Feuerstein C, Demenge P. Rostrocaudal localization of cardiovascular responses induced by intrathecal administration of apomorphine in conscious, freely moving rats. J Cardiovasc Pharmacol 1990 ; 16: 331-7
32. 2 receptor agonists and antagonists. J Cardiovasc Pharmacol 1991 ; 18: 548-55
33. Lahlou S, Demenge P. Cardiovascular responses to intrathecal dopamine receptor agonists after spinal transection in conscious rats. Cardiovasc Res 1993 ; 27: 222-30
34. Takano Y, Martin JE, Leeman SE, Loewy AD. Substance P immunoreactivity released from rat spinal cord after kainic acid excitation of the ventral medulla oblongata: a correlation with increases in blood pressure. Brain Res 1984 ; 291: 168-72
35. 2 receptor agonist, in the anesthetized rat. J Pharmacol Exp Ther 1986 ; 239: 426-32
36. 2 dopamine receptor agonist quinpirole in rats. Fundam Clin Pharmacol 1987 ; 1: 179-200
37. Roquebert J, Moran A, Sauvage MF, Demichel P. Effects of quinpirole on autonomic nervous control of heart rate in rats. Fundam Clin Pharmacol 1992 ; 6: 67-73
38. Peringer E, Jenner P, Donaldson IM, Marsden CD. Metoclopramide and dopamine receptor blockade. Neuropharmacology 1976; 15: 463-9
39. Cavero I, Massingham R, Lefevre-Borg F. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description. Life Sci 1982 ; 31: 939-48
40. Kubo T, Nagura J, Misu Y. Pharmacological characterization of spinal alpha adrenoceptors related to blood pressure control in rats. J Pharmacol Exp Ther 1987 ; 240: 298-302
41. Gradin K. Interactions between substance P and serotonergic mechanisms at preganglionic sympathetic nerves in thoracic spinal card. Acta Physiol Scand 1990 ; 138: 101-2
42. Gibson A, Samini M, Bromocriptine is a potent alpha-adrenoceptor antagonist in the perfused mesenteric blood vessels of the rat. J Pharm Pharmacol 1978 ; 30: 314-5
43. Langer SZ. Comparative analysis of presynaptic inhibition of noradrenaline release by alpha-2 and dopamine receptors. Acta Pharmacol Toxicol 1981 ; 49: 20-1
44. Cavero I, Massingham R, Lefevre-Borg F. Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists. Life Sci 1982 ; 31: 1059-69
45. Willems JL, Buylaert WA, Lefevre RA, Bogaert MG. Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol Rev 1985 ; 37: 165-216
46. Kopin IJ, Lake RC, Ziegler M. Plasma levels of norepinephrine. Ann Intern Med 1978 ; 88: 671-80
47. Sengupta S, Lokhandwala MF. Characterization of the hypotensive action of dopamine receptor agonists fenoldopam and quinpirole in anesthetized rats. J Auton Pharmacol 1985 ; 5: 289-94
48. Cavero I, Thiry C, Pratz J, Lawson K. Cardiovascular characterization of DA-1 and DA-2 dopamine receptor agonists in anesthetized rats. Clin Exp Hypertens 1987 ; A9: 931-52
49. Kurz K, Main B, Moore R, Smith T. Differential effects of the selective dopamine (DA) agonist, quinpirole, on blood pressure in conscious normotensive and hypertensive rats. Fed Proc 1986; 45: 1071 (Abstract)
50. 2 receptor agonist, in the conscious rat. J Pharmacol Exp Ther 1986 ; 236: 735-42
51. 2 receptor agonist: studies in conscious Brattleboro and Long-Evans rats. J Pharmacol Exp Ther 1987 ; 242: 143-51
52. 2 receptor agonist, in conscious deoxycorticosterone acetate/NaCl hypertensive rats is related to atrial natriuretic peptide release. J Pharmacol Exp Ther 1988 ; 246: 485-92
53. Creese I, Iversen SD. Blockade of amphetamine-induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-OHDA. Brain Res 1973 ; 55: 396-402